1
|
Morrow K, Young KA, Spencer S, Medina ES, Marziale MA, Sanchez A, Bourgeois JA. Utility of oxcarbazepine in the treatment of childhood and adolescent psychiatric symptoms. Proc AMIA Symp 2020; 34:34-39. [PMID: 33456141 PMCID: PMC7785147 DOI: 10.1080/08998280.2020.1826259] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
The primary aims of this study were to determine if oxcarbazepine is a safely tolerated option for treatment of psychiatric symptoms in children and whether its use facilitates dose modification of other psychotropic medications. A retrospective chart review was completed using data extracted from the electronic medical record of a large outpatient child psychiatry clinic. A total of 507 of 740 children prescribed oxcarbazepine for psychiatric indications for 3 months or more had adequate data to assess clinical responses and medication outcomes. Most patients prescribed oxcarbazepine experienced clinically significant control of irritability/anger, mood stabilization, aggressive outbursts, impulsivity, or anxiety, with over 80% achieving at least maintenance symptom control. In all, 51% and 25% fully discontinued second- or third-generation antipsychotic or antidepressant medication, respectively, after starting oxcarbazepine; 8% discontinued oxcarbazepine for nonresponse, while 9% stopped oxcarbazepine because of emergent side effects. In patients fully discontinuing or reducing the second- or third-generation antipsychotic dose by 50% or more, improvements in body mass index were observed. Oxcarbazepine may prove to be an appropriate alternative to antipsychotic and antidepressant medications for treating psychiatric symptoms in children and adolescents. In particular, it may be a more metabolically neutral psychotropic medication.
Collapse
Affiliation(s)
- Kyle Morrow
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - Keith A Young
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - Shawn Spencer
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - Edgar Samuel Medina
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - Michaela A Marziale
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - Alejandro Sanchez
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| | - James A Bourgeois
- Department of Psychiatry, Baylor Scott & White Health, Central Texas Division, and College of Medicine, Texas A&M University Health Science Center, Temple, Texas
| |
Collapse
|
2
|
Kaufman KR. Epilepsy & behavior: a professional and a personal home. Epilepsy Behav 2014; 40:2-3. [PMID: 25258052 DOI: 10.1016/j.yebeh.2014.08.032] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/18/2014] [Accepted: 08/19/2014] [Indexed: 11/19/2022]
Affiliation(s)
- Kenneth R Kaufman
- Department of Psychiatry, Rutgers Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA; Department of Neurology, Rutgers Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA; Department of Anesthesiology, Rutgers Robert Wood Johnson Medical School, 125 Paterson Street, Suite #2200, New Brunswick, NJ 08901, USA.
| |
Collapse
|
3
|
Abstract
Anticonvulsants are being used clinically as monotherapy and adjuncts in mental illnesses other than affective disorders. This review focuses on the literature for anticonvulsants and lithium in substance use disorders, anxiety disorders, and schizophrenia. Given the abuse potential and other difficulties with prescribing benzodiazepines for alcohol and benzodiazepine withdrawal, anticonvulsants have been considered as an alternative. Promising therapeutic effects have been demonstrated in many of the anxiety disorders, with the greatest number of trials and positive results in posttraumatic stress disorder. Although anticonvulsant and lithium augmentation for schizophrenia is common in practice and has been studied in double-blind, randomized, controlled trials, the sum of the evidence has been inconclusive.
Collapse
|